AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ionis Pharmaceuticals (IONS) Soars 17.32% on FDA Approval
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Sep 2, 2025 8:13 am ET1min read
Aime SummaryIonis Pharmaceuticals (IONS) surged 17.32% in pre-market trading on September 2, 2025, driven by significant developments in its drug pipeline and regulatory approvals.
Ionis Pharmaceuticals received FDA approval for its hereditary angioedema (HAE) drug, marking a major milestone for the company. This approval is expected to boost the company's revenue and market position. Additionally,
has lifted its target price for , reflecting the positive outlook on the company's prospects.Another key development is the FDA's decision on Donidalorsen, an investigational RNA-targeted medicine developed by Ionis Pharmaceuticals. The decision, expected on August 21, 2025, could further impact the company's stock performance. Donidalorsen is a promising drug that targets specific RNA sequences, offering potential therapeutic benefits for various diseases.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Compass Pathways surges 5.51% in pre-market trading driven by mental health sector optimism
Dec.24 2025
United States Antimony shares surged 7.87% on strategic operational updates and sector tailwinds.
Dec.24 2025
UAMY shares surge 7.87% on strategic expansion and operational milestones
Dec.24 2025
COMPASS Pathways Shares Surge 5.51% on Strategic Partnership and Clinical Progress
Dec.24 2025
Vestis plunges 6.30% in pre-market trading amid sector-wide volatility and macroeconomic uncertainties
Dec.24 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet